Powder: -20°C for 3 years
In solvent: -80°C for 2 years
FRAX-1036 is a effective and selective PAK1 inhibitor.
Description | FRAX-1036 is a effective and selective PAK1 inhibitor. |
Targets&IC50 | PAK1:23.3 nM(Ki), PAK2:72.4 nM(Ki), PAK4:2.4 μM(Ki) |
In vitro | MDA-MB-175 cells,which are PAK1-amplified (MEK1-S298 and CRAF-S338) ,was observed Potent cellular inhibition at 2.5 to 5 μM concentrations of FRAX1036. PAK1-amplified breast cancer cells are treated with FRAX1036 leading to apoptosis. OVCAR-3 cells are treated with FRAX-1036 resulting in upregulation of p53 and p21, while down-regulating cyclin B1. |
In vivo | KT21 are treated with Frax1036 showing slower tumor growth, while Frax1036 is unlikely to have significant blood-brain barrier permeability in mice. |
Cell Research | MDA-MB175 cells are treated with increasing concentrations (0, 0.5, 1, 2.5, 5 μM) of FRAX1036 for 24 hours. |
Animal Research | Pak2-deficient mice were treated by oral gavage of 30 mg/kg Frax1036. |
Molecular Weight | 518.06 |
Formula | C28H32ClN7O |
CAS No. | 1432908-05-8 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: insoluble
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FRAX1036 1432908-05-8 细胞骨架 PAK FRAX 1036 Inhibitor p21 activated kinases inhibit FRAX-1036 inhibitor